Report of Foreign Issuer (6-k)
July 02 2020 - 4:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
For the month of July 2020
Commission File Number: 001-36582
Auris Medical Holding Ltd.
(Exact name of registrant as specified in
its charter)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐
No ☒
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐
No ☒
Reduction of the par value of the Company’s common shares
As previously announced, on June 4, 2020, the
shareholders of Auris Medical Holding Ltd. (the “Company”) approved the reduction of the issued share capital
of the Company by reducing the par value of each common share of the Company in issue from CHF 0.40 to CHF 0.01 (the “Reduction”)
with effect from not before June 4, 2020 and no later than June 30, 2020 (the “Effective Date”), which date
the Board of Directors of the Company subsequently resolved to be June 30, 2020, provided the Company satisfied the requirements
of section 46(2) of the Companies Act 1981, as amended of Bermuda on the Effective Date.
On June 30, 2020, the Reduction took effect,
the issued share capital of the Company was reduced from CHF 2,023,633.60 to CHF 50,590.84, the amount of such reduction was credited
to the contributed surplus account of the Company and the authorized share capital of the Company attributable to common shares
was reduced to CHF 250,000, divided into 25,000,000 common shares of CHF 0.01 each.
INCORPORATION BY REFERENCE
This Report on Form 6-K
shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-228121)
and Form S-8 (Registration Number 333-232735) of Auris Medical Holding Ltd. and to be a part thereof from the date on which
this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Auris Medical Holding Ltd.
|
|
|
|
By:
|
/s/ Thomas Meyer
|
|
|
Name:
|
Thomas Meyer
|
|
|
Title:
|
Chairman and Chief Executive Officer
|
Date: July 2, 2020
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024